Title:
PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTI-TUMOR EFFECT OF EZH2 INHIBITOR, AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/061446
Kind Code:
A1
Abstract:
The present invention belongs to the field of medicine. Provided is a pharmaceutical composition for enhancing the anti-tumor effect of an EZH2 inhibitor. The pharmaceutical composition comprises an EZH2 inhibitor and a PPARα agonist, wherein the PPARα agonist enhances the anti-solid tumor effect of the EZH2 inhibitor.
Further provided in the present invention are a related preparation of the pharmaceutical composition and the use thereof in the preparation of an anti-tumor drug.
Experimental results show that when the EZH2 inhibitor GSK126 and the PPARα agonist fenofibrate are used in combination to treat B16F10 cells, SMMC7721 cells and GL261 cells, it is found that the use thereof in combination with fenofibrate can significantly enhance the inhibitory effect of GSK126 on cell proliferation. The pharmaceutical composition of the present invention provides a new thought for the clinical treatment of solid tumors by means of safely, effectively, conveniently and economically using the EZH2 inhibitor, has good clinical application prospects, and provides evidence for a new use of the conventional drug fenofibrate.
Inventors:
XUE LIXIANG (CN)
WANG YAN (CN)
ZHANG TENGRUI (CN)
GUO ZHENGYANG (CN)
GONG YUEQING (CN)
YAN QIANQIAN (CN)
SUN YAN (CN)
MENG HUI (CN)
MA XIAOJUAN (CN)
WANG YAN (CN)
ZHANG TENGRUI (CN)
GUO ZHENGYANG (CN)
GONG YUEQING (CN)
YAN QIANQIAN (CN)
SUN YAN (CN)
MENG HUI (CN)
MA XIAOJUAN (CN)
Application Number:
PCT/CN2022/125101
Publication Date:
April 20, 2023
Filing Date:
October 13, 2022
Export Citation:
Assignee:
UNIV PEKING THIRD HOSPITAL (CN)
International Classes:
A61K45/06; A61K31/216; A61K31/445; A61K31/496; A61K31/5377; A61P35/00
Foreign References:
| CN112972688A | 2021-06-18 |
Other References:
HU JILONG, ZHENG ZHINAN, LEI JIA, CAO YUXIN, LI QIYUN, ZHENG ZHI, CHEN CHUANJUN: "Targeting the EZH2-PPAR Axis Is a Potential Therapeutic Pathway for Pancreatic Cancer", PPAR RESEARCH, HINDAWI PUBLISHING CORP., US, vol. 2021, 22 July 2021 (2021-07-22), US , pages 1 - 12, XP093058212, ISSN: 1687-4757, DOI: 10.1155/2021/5589342
MENG HUI, GUO ZHENG-YANG ，ZHANG TENG-ＲUI , YIN ZHONG-NAN , GONG YUE-QING, LI CHEN ，XUE LI-XIANG: "Fenofibrate Inhibits Proliferation of Cancer Cells by Activating Hippo Signaling Pathway", ZHONGGUO SHENGWU HUAXUE YU FENZI SHENGWU XUEBAO - CHINESE JOURNAL OF BIOCHEMISTRY AND MOLECULAR BIOLOGY, BEIJING DAXUE YIXUEBU, CN, vol. 36, no. 6, 30 June 2020 (2020-06-30), CN , pages 674 - 679, XP093058214, ISSN: 1007-7626
CHEN LI;YAN WANG;YUEQING GONG;TENGRUI ZHANG;JIAQI HUANG;ZHEN TAN;LIXIANG XUE: "Finding an easy way to harmonize: a review of advances in clinical research and combination strategies of EZH2 inhibitors", CLINICAL EPIGENETICS, BIOMED CENTRAL LTD, LONDON, UK, vol. 13, no. 1, 24 March 2021 (2021-03-24), London, UK, pages 1 - 12, XP021288421, ISSN: 1868-7075, DOI: 10.1186/s13148-021-01045-1
MENG HUI, GUO ZHENG-YANG ，ZHANG TENG-ＲUI , YIN ZHONG-NAN , GONG YUE-QING, LI CHEN ，XUE LI-XIANG: "Fenofibrate Inhibits Proliferation of Cancer Cells by Activating Hippo Signaling Pathway", ZHONGGUO SHENGWU HUAXUE YU FENZI SHENGWU XUEBAO - CHINESE JOURNAL OF BIOCHEMISTRY AND MOLECULAR BIOLOGY, BEIJING DAXUE YIXUEBU, CN, vol. 36, no. 6, 30 June 2020 (2020-06-30), CN , pages 674 - 679, XP093058214, ISSN: 1007-7626
CHEN LI;YAN WANG;YUEQING GONG;TENGRUI ZHANG;JIAQI HUANG;ZHEN TAN;LIXIANG XUE: "Finding an easy way to harmonize: a review of advances in clinical research and combination strategies of EZH2 inhibitors", CLINICAL EPIGENETICS, BIOMED CENTRAL LTD, LONDON, UK, vol. 13, no. 1, 24 March 2021 (2021-03-24), London, UK, pages 1 - 12, XP021288421, ISSN: 1868-7075, DOI: 10.1186/s13148-021-01045-1
Attorney, Agent or Firm:
BEIJING CEMO LEADER INTELLECTUAL PROPERTY AGENCY (CN)
Download PDF: